A clinical-stage biopharmaceutical company focused on developing human polyclonal immunotherapeutic antibodies to treat immune system disorders and infectious diseases. The company's lead product candidate, SAB-142, is in Phase 2b clinical trials for autoimmune type 1 diabetes treatment.